Skip to main content
Erschienen in: Pathology & Oncology Research 4/2010

01.12.2010

Elevated Osteopontin Expression and Proliferative/Apoptotic Ratio in the Colorectal Adenoma–Dysplasia–Carcinoma Sequence

verfasst von: Gábor Valcz, Ferenc Sipos, Tibor Krenács, Jeannette Molnár, Árpád V. Patai, Katalin Leiszter, Kinga Tóth, Norbert Solymosi, Orsolya Galamb, Béla Molnár, Zsolt Tulassay

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer progression is characterized by altered epithelial proliferation and apoptosis and by changed expression of tumor development regulators. Our aims were to determine the proliferative/apoptotic epithelial cell ratio (PAR) in the adenoma–dysplasia–carcinoma sequence (ADCS), and to examine its association with osteopontin (OPN), a previously identified protein product related to cancer development. One mm diameter cores from 13 healthy colons, 13 adenomas and 13 colon carcinoma samples were included into a tissue microarray (TMA) block. TUNEL reaction and Ki-67 immunohistochemistry were applied to determine the PAR. The osteopontin protein was also immunodetected. Stained slides were semiquantitatively evaluated using digital microscope and statistically analyzed with logistic regression and Fisher’s exact test. The PAR continuously increased along the ADCS. It was significantly (p < 0.001) higher in cancer epithelium (8.84 ± 7.01) than in adenomas (1.40 ± 0.78) and in normal controls (0.89 ± 0.21) (p < 0.001). Also, significant positive correlation was observed between elevated PAR and the expression of osteopontin. Cytoplasmic OPN expression was weak in healthy samples. In contrast, cytoplasmic immunoreaction was moderately intensive in adenomas, while in colon cancer strong, diffuse cytoplasmic immune staining was detected. Increasing PAR and OPN expression along ADCS may help monitoring colorectal cancer progression. The significantly elevated OPN protein levels we found during normal epithelium to carcinoma progression may contribute to the increased fibroblast–myofibroblast transition determining stem cell niche in colorectal cancer.
Literatur
1.
Zurück zum Zitat Burgess AW (1998) Growth control mechanisms in normal and transformed intestinal cells. Philos Trans R Soc Lond B Biol Sci 353:903–909CrossRefPubMed Burgess AW (1998) Growth control mechanisms in normal and transformed intestinal cells. Philos Trans R Soc Lond B Biol Sci 353:903–909CrossRefPubMed
2.
3.
Zurück zum Zitat Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767CrossRefPubMed Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767CrossRefPubMed
4.
Zurück zum Zitat Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532CrossRefPubMed Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532CrossRefPubMed
5.
Zurück zum Zitat Leslie A, Carey FA, Pratt NR et al (2002) The colorectal adenoma–carcinoma sequence. Br J Surg 89:845–860CrossRefPubMed Leslie A, Carey FA, Pratt NR et al (2002) The colorectal adenoma–carcinoma sequence. Br J Surg 89:845–860CrossRefPubMed
6.
Zurück zum Zitat Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRefPubMed Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRefPubMed
7.
Zurück zum Zitat Sipos F, Zágoni T, Molnár B et al (2002) Changes in the proliferation and apoptosis of colonic epithelial cells in correlation with histologic activity of ulcerative colitis. Orv Hetil 143:2485–2488PubMed Sipos F, Zágoni T, Molnár B et al (2002) Changes in the proliferation and apoptosis of colonic epithelial cells in correlation with histologic activity of ulcerative colitis. Orv Hetil 143:2485–2488PubMed
8.
Zurück zum Zitat Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419–429CrossRefPubMed Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419–429CrossRefPubMed
9.
Zurück zum Zitat Galamb O, Sipos F, Spisák S et al (2009) Potential biomarkers of colorectal adenoma–dysplasia–carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol 31:19–29PubMed Galamb O, Sipos F, Spisák S et al (2009) Potential biomarkers of colorectal adenoma–dysplasia–carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol 31:19–29PubMed
10.
Zurück zum Zitat Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103–118CrossRefPubMed Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103–118CrossRefPubMed
11.
Zurück zum Zitat Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87CrossRefPubMed Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87CrossRefPubMed
12.
Zurück zum Zitat Bautista DS et al (1994) Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269:23280–23285PubMed Bautista DS et al (1994) Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269:23280–23285PubMed
13.
Zurück zum Zitat Hirama M, Takahashi F, Takahashi K et al (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107–117CrossRefPubMed Hirama M, Takahashi F, Takahashi K et al (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107–117CrossRefPubMed
15.
Zurück zum Zitat Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030CrossRefPubMed Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030CrossRefPubMed
16.
Zurück zum Zitat Huang W, Carlsen B, Rudkin G et al (2004) Osteopontin is a negative regular of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 34:799–808CrossRefPubMed Huang W, Carlsen B, Rudkin G et al (2004) Osteopontin is a negative regular of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 34:799–808CrossRefPubMed
17.
Zurück zum Zitat Panda D, Kundu GC, Lee BI et al (1997) Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA 94:9308–9313CrossRefPubMed Panda D, Kundu GC, Lee BI et al (1997) Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA 94:9308–9313CrossRefPubMed
18.
Zurück zum Zitat Elgavish A, Prince C, Chang PL (1998) Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro. Prostate 35:83–94CrossRefPubMed Elgavish A, Prince C, Chang PL (1998) Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro. Prostate 35:83–94CrossRefPubMed
19.
Zurück zum Zitat El-Tanani MK, Campbell FC, Kurisetty V et al (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17:463–474CrossRefPubMed El-Tanani MK, Campbell FC, Kurisetty V et al (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17:463–474CrossRefPubMed
20.
Zurück zum Zitat Lenga Y, Koh A, Perera AS et al (2008) Osteopontin expression is required for myofibroblast differentiation. Circ Res 102:319–327CrossRefPubMed Lenga Y, Koh A, Perera AS et al (2008) Osteopontin expression is required for myofibroblast differentiation. Circ Res 102:319–327CrossRefPubMed
21.
Zurück zum Zitat Saika S, Shirai K, Yamanaka O et al (2007) Loss of osteopontin perturbs the epithelial–mesenchymal transition in an injured mouse lens epithelium. Lab Invest 87:130–138CrossRefPubMed Saika S, Shirai K, Yamanaka O et al (2007) Loss of osteopontin perturbs the epithelial–mesenchymal transition in an injured mouse lens epithelium. Lab Invest 87:130–138CrossRefPubMed
22.
Zurück zum Zitat Miyazaki K, Okada Y, Yamanaka O et al (2008) Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 49:1367–1375CrossRefPubMed Miyazaki K, Okada Y, Yamanaka O et al (2008) Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 49:1367–1375CrossRefPubMed
23.
Zurück zum Zitat Junaid A, Moon MC, Harding GE et al (2007) Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 292:919–926CrossRef Junaid A, Moon MC, Harding GE et al (2007) Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 292:919–926CrossRef
24.
Zurück zum Zitat Katenkamp D, Berndt R, Perevoshchikov A et al (1984) Ultrastructural observations of the stroma of human colon carcinomas with special regard to myofibroblasts. Arch Geschwulstforsch 54:301–308PubMed Katenkamp D, Berndt R, Perevoshchikov A et al (1984) Ultrastructural observations of the stroma of human colon carcinomas with special regard to myofibroblasts. Arch Geschwulstforsch 54:301–308PubMed
25.
Zurück zum Zitat Hawinkels LJ, Verspaget HW, van der Reijden JJ et al (2009) Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma–carcinoma sequence. Cancer Sci 100:663–670CrossRefPubMed Hawinkels LJ, Verspaget HW, van der Reijden JJ et al (2009) Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma–carcinoma sequence. Cancer Sci 100:663–670CrossRefPubMed
26.
Zurück zum Zitat Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed
27.
Zurück zum Zitat Dai J, Li B, Shi J et al (2010) A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 59:355–366CrossRefPubMed Dai J, Li B, Shi J et al (2010) A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 59:355–366CrossRefPubMed
28.
Zurück zum Zitat Thalmann GN, Sikes RA, Devoll RE et al (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMed Thalmann GN, Sikes RA, Devoll RE et al (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMed
Metadaten
Titel
Elevated Osteopontin Expression and Proliferative/Apoptotic Ratio in the Colorectal Adenoma–Dysplasia–Carcinoma Sequence
verfasst von
Gábor Valcz
Ferenc Sipos
Tibor Krenács
Jeannette Molnár
Árpád V. Patai
Katalin Leiszter
Kinga Tóth
Norbert Solymosi
Orsolya Galamb
Béla Molnár
Zsolt Tulassay
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2010
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9260-z

Weitere Artikel der Ausgabe 4/2010

Pathology & Oncology Research 4/2010 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.